OPEN END TURBO LONG - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 01:17:09 2024-06-21 pm EDT | ||
| 28.75 EUR / 28.8 EUR | -0.81% |
|
| Current month | +7.80% | ||
| 1 month | +9.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 28.97 | -0.14% |
| 24-06-20 | 29.01 | +2.04% |
| 24-06-19 | 28.43 | -1.32% |
| 24-06-18 | 28.81 | -2.31% |
| 24-06-17 | 29.49 | -2.12% |
Delayed Quote Börse Stuttgart
Last update June 21, 2024 at 10:20 am EDT
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MC1UYN |
| ISIN | DE000MC1UYN0 |
| Date issued | 2019-05-22 |
| Strike | 160.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.19 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 30.16 € |
|---|---|
| Lowest since issue | 3.72 € |
| Spread | 0.05 € |
| Spread % | 0.17% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
471.4
USD
Average target price
463.4
USD
Spread / Average Target
-1.69%
- Stock Market
- Certificates
- Certificat
